AbbVie Inc. [NYSE: ABBV] jumped around 1.58 points on Tuesday, while shares priced at $96.17 at the close of the session, up 1.67%. AbbVie Inc. stock is now 8.62% up from its year-to-date (YTD) trading value. ABBV Stock saw the intraday high of $96.66 and lowest of $94.76 per share. The company’s 52-week high price is 97.86, which means current price is +53.75% above from all time high which was touched on 02/12/20.
Compared to the average trading volume of 13.04M shares, ABBV reached a trading volume of 8961902 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
What do top market gurus say about AbbVie Inc. [ABBV]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABBV shares is $97.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABBV stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wolfe Research have made an estimate for AbbVie Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 09, 2020. The new note on the price target was released on June 02, 2020, representing the official price target for AbbVie Inc. stock. Previously, the target price had yet another raise to $95, while BofA/Merrill analysts kept a Neutral rating on ABBV stock.
The Average True Range (ATR) for AbbVie Inc. is set at 2.62, with the Price to Sales ratio for ABBV stock in the period of the last 12 months amounting to 4.93. Price to Free Cash Flow for ABBV in the course of the last twelve months was 23.97 with Quick ratio for the last quarter at 3.00.
How has ABBV stock performed recently?
AbbVie Inc. [ABBV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.63. With this latest performance, ABBV shares gained by 14.54% in over the last four-week period, additionally plugging by 10.57% over the last 6 months – not to mention a rise of 24.98% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABBV stock in for the last two-week period is set at 70.82, with the RSI for the last a single of trading hit 74.46, and the three-weeks RSI is set at 65.42 for AbbVie Inc. [ABBV]. The present Moving Average for the last 50 days of trading for this stock 85.23, while it was recorded at 93.71 for the last single week of trading, and 82.56 for the last 200 days.
AbbVie Inc. [ABBV]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and AbbVie Inc. [ABBV] shares currently have an operating margin of +41.83 and a Gross Margin at +77.14. AbbVie Inc.’s Net Margin is presently recorded at +23.57.
Return on Total Capital for ABBV is now 30.66, given the latest momentum, and Return on Invested Capital for the company is 19.22. Additionally, ABBV Total Debt to Total Capital is recorded at 113.87, with Total Debt to Total Assets ending up at 75.28.
Reflecting on the efficiency of the workforce at the company, AbbVie Inc. [ABBV] managed to generate an average of $261,400 per employee. Receivables Turnover for the company is 5.89 with a Total Asset Turnover recorded at a value of 0.45.AbbVie Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.00 and a Current Ratio set at 3.10.
Earnings analysis for AbbVie Inc. [ABBV]
With the latest financial reports released by the company, AbbVie Inc. posted 2.26/share EPS, while the average EPS was predicted by analysts to be reported at 2.21/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 2.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABBV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbbVie Inc. go to 10.25%.
Insider trade positions for AbbVie Inc. [ABBV]
There are presently around $127,208 million, or 63.30% of ABBV stock, in the hands of institutional investors. The top three institutional holders of ABBV stocks are: VANGUARD GROUP INC with ownership of 147,377,065, which is approximately 2.49% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 119,686,187 shares of the stock with an approximate value of $11.32 billion in ABBV stocks shares; and STATE STREET CORP, currently with $7.58 billion in ABBV stock with ownership of nearly -1.475% of the company’s market capitalization.
Positions in AbbVie Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 1,224 institutional holders increased their position in AbbVie Inc. [NYSE:ABBV] by around 124,299,007 shares. Additionally, 1,128 investors decreased positions by around 104,758,541 shares, while 234 investors held positions by with 1,115,777,142 shares. The mentioned changes placed institutional holdings at 1,344,834,690 shares, according to the latest SEC report filing. ABBV stock had 155 new institutional investments in for a total of 8,408,149 shares, while 154 institutional investors sold positions of 5,350,406 shares during the same period.